Table 1.
Characteristics of the study population.
| Characteristics | Numbers of cases (%) |
|---|---|
| Age | |
| NA | 2 (0.18) |
| <60 | 589 (53.35) |
| ≥60 | 513 (46.47) |
| Gender | |
| NA | 2 (0.18) |
| Female | 1090 (98.73) |
| Male | 12 (1.09) |
| Histological type | |
| NA | 3 (0.27) |
| Infiltrating ductal carcinoma | 790 (71.56) |
| Infiltrating lobular carcinoma | 204 (18.48) |
| Other | 107 (9.69) |
| Molecular subtype | |
| NA | 255 (23.1) |
| Basal | 142 (12.86) |
| HER-2 | 67 (6.07) |
| Luminal A | 422 (38.22) |
| Luminal B | 194 (17.57) |
| Normal | 24 (2.17) |
| ER | |
| NA | 50 (4.53) |
| Indeterminate | 2 (0.18) |
| Negative | 239 (21.65) |
| Positive | 813 (73.64) |
| PR | |
| NA | 51 (4.62) |
| Indeterminate | 4 (0.36) |
| Negative | 345 (31.25) |
| Positive | 704 (63.77) |
| HER-2 | |
| NA | 183 (16.58) |
| Equivocal | 180 (16.3) |
| Indeterminate | 12 (1.09) |
| Negative | 565 (51.18) |
| Positive | 164 (14.86) |
| Menopause status | |
| NA | 93 (8.42) |
| Indeterminate | 34 (3.08) |
| Peri | 40 (3.62) |
| Post | 706 (63.95) |
| Pre | 231 (20.92) |
| T classification | |
| NA | 2 (0.18) |
| T1 | 281 (25.45) |
| T2 | 640 (57.97) |
| T3 | 138 (12.5) |
| T4 | 40 (3.62) |
| TX | 3 (0.27) |
| N classification | |
| NA | 2 (0.18) |
| N0 | 516 (46.74) |
| N1 | 367 (33.24) |
| N2 | 120 (10.87) |
| N3 | 79 (7.16) |
| NX | 20 (1.81) |
| M classification | |
| NA | 2 (0.18) |
| M0 | 917 (83.06) |
| M1 | 22 (1.99) |
| MX | 163 (14.76) |
| TNM stage | |
| NA | 10 (0.91) |
| I | 182 (16.49) |
| II | 626 (56.7) |
| III | 252 (22.83) |
| IV | 20 (1.81) |
| X | 14 (1.27) |
| Margin status | |
| NA | 72 (6.52) |
| Close | 31 (2.81) |
| Negative | 922 (83.51) |
| Positive | 79 (7.16) |
| Vital status | |
| NA | 2 (0.18) |
| Deceased | 155 (14.04) |
| Living | 947 (85.78) |
| Radiation therapy | |
| NA | 102 (9.24) |
| No | 445 (40.31) |
| Yes | 557 (50.45) |
| Neoadjuvant treatment | |
| NA | 3 (0.27) |
| No | 1088 (98.55) |
| Yes | 13 (1.18) |
| Targeted molecular therapy | |
| NA | 525 (47.55) |
| No | 46 (4.17) |
| Yes | 533 (48.28) |
| Sample type | |
| Metastatic | 7 (0.63) |
| Primary tumor | 1097 (99.37) |
| OS | |
| NA | 17 (1.54) |
| 0 | 933 (84.51) |
| 1 | 154 (13.95) |
| RFS | |
| NA | 192 (17.39) |
| 0 | 816 (73.91) |
| 1 | 96 (8.70) |
| ZNF385B | |
| High | 804 (72.83) |
| Low | 300 (27.17) |
ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor-2; T: tumor; M: metastasis; N: node; OS: overall survival; RFS: relapse-free survival; NA: not available.